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We herein report a faster and less cumbersome synthesis of the biologically attractive, α-galactosyl
ceramide (α-GalCer), known as KRN7000, and its analogues. More importantly, the use of a silicon
tethered intramolecular glycosylation reaction gave easy access to the diglycosyl ceramide Gal
(α1→2)GalCer, which has been shown to require uptake and processing to the biologically active
α-GalCer derivative.
Keywords
CD1d; KRN7000; iNKT; Galactosyl(α1-2)galactosyl
CD1d is a nonpolymorphic glycoprotein expressed on the surface of antigen-presenting cells
(APCs). It is specifically associated with presenting lipid antigens that activate the distinctive
class of T cells, known as invariant Natural Killer T (iNKT) cells. iNKT cells display
characteristics of both T cells and NK cells and play a crucial role in diverse immune responses
and other pathologic conditions. When the synthetic glycolipid α-galactosyl ceramide (α-
GalCer), known as KRN7000 (1), is bound to CD1d and presented to the T cell receptors
(TCRs) on the surface of iNKT cells, the latter are activated to release diverse cytokines,
including both Th1 and Th2 cytokines. It is believed that the release of Th1 cytokines may
contribute to antitumour and antimicrobial functions while that of Th2 cytokines may help
alleviate autoimmune diseases such as multiple sclerosis and arthritis. α-GalCer and its
derivatives have proved to be and remain invaluable tools in understanding the functioning of
CD1d and NKT cells in a wide range of immune responses. As part of various ongoing studies,
easy access to relatively extensive quantities of these substrates is, therefore, required.
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make use of benzyl ether protecting groups on the sugar moiety. We, along with many other
research groups, have encountered difficulties in the hydrogenolysis of benzyl ethers, thereby
leading to low yields of α-GalCer. Therefore, synthetic routes circumventing the problematic
hydrogenolysis step are highly desired. Kiso and co-workers recently reported such a synthesis,
where interestingly they also made use of the bulky 4,6-O-di-tert-butylsilylene (DTBS) group
as α-directing in galactosylation donor 3.
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to obtain the glycosylated sphingoid base template 2, which can readily be converted to α-
GalCer and other derivatives. Initially, to improve on the reported synthesis we resorted to the
use of the thioglycosyl donor 4 as it is easier to handle and has a better shelf life than the
trichloroacetimidate donor 3. Significantly, the second route describes a novel synthesis of α-
GalCer and has the additional benefit of providing a crucial intermediate, which can be further
modified to yield other biologically active α-GalCer derivatives.
We first synthesized the phytosphingosine acceptor 5 from (2S,3S,4R)-2-azido-1, 3, 4-
octadecanetriol in three steps as described in Scheme 1.
The thioglycoside 4 was obtained in large scale from commercially available β-D-
galactopyranose pentaacetate after standard procedures, as described previously.The critical
glycosylation was then attempted on 2 g of the donor 4. NIS/TfOH activation of thioglycoside
4 (Scheme 2) in anhydrous CH2Cl2 at −78 °C afforded the glycosylated compound 6 in 71%
yield, as the α-anomer exclusively after two hours. Subsequent sequential removal of the silyl
group with TBAF and Zemplen’s deprotection of the benzoate protecting groups produced the
azide intermediate in quantitative yields after purification by flash chromatography. Different
methods for the reduction of the azide group were attempted, including the use hydrogen
sulfide, but the best results were obtained via hydrogenation in methanol. 800 mg of the amine
2 was hence isolated as a white solid.
Scheme 3 illustrates our novel strategy to synthesise α-GalCer and its derivatives. Silicon
tethered intramolecular glycosylation is a particularly attractive method for generating
glycosidic bonds stereoselectively, but not attempted by many research groups due to the
difficulty in handling and relative instability of the silylene-tethered sugar derivative. However,
successful examples have been reported and we were motivated by Bols work on the synthesis
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chloride (7) was obtained from β-D-galactopyranose pentaacetate and converted to the
corresponding thioglycoside 8 by reacting with thiophenol in the presence of caesium
carbonate. The tethered compound 9 was then synthesised following the procedure described
by Bols. Rearrangement of the silylene 9, catalyzed by N-iodosuccinimide (NIS) in anhydrous
nitromethane at 80 °C, yielded the desired product 10 along with some small amounts of 5
after 2 h. It was observed that by careful monitoring and quenching of the reaction as soon as
compound 9 was consumed, helped in minimizing the regeneration of phytosphingosine
derivative 5 and hence enhanced the yield of the glycosylated product. Methanolysis, followed
by hydrogenation of the azide then afforded compound 2. Finally, N-acylation with the fully
saturated fatty acid, hexacosanoic acid, was achieved via reaction of the corresponding acid
chloride with the free amine 2 in a 1:1 mixture of THF and saturated sodium acetate solution.
Target compound 1 was obtained as a white solid after concentration of the organic phase and
purification of the residue by flash chromatography. The spectroscopic data of the latter were
consistent with the literature.
While our first approach (Scheme 2) is more direct and higher yielding, the alternative route
(Scheme 3) also provides the additional benefit of freeing the hydroxyl group at C-2 on the
sugar residue (compound 10). This allows for selective modification on α-GalCer; such as the
introduction of an additional sugar residue. Specifically, the diglycosyl ceramide, Gal
(α1→2GalCer) 12 has been used to study lysosomal glycolipid processing. Briefly,
galactosidases from lysosomes are responsible for truncating oligoglycosyl ceramides to
monoglycosyl ceramides before they can bind to CD1d and be presented to iNKT cells. Scheme
4 depicts a new strategy for synthesizing disaccharide 11 via NIS/TfOH activation of sugar
donor 4 at −78 °C in anhydrous CH2Cl2 for 3 h. Once more, the directing effect of the bulky
silyl group ensured the formation of the desired α-linkage, as confirmed by the H-1 and C-1
signals in 1H and 13C NMR. Compound 12 was obtained after routine procedures, similar to
those described above and exhibited spectroscopic data consistent with the literature.
We next tested the biological activity of α-GalCer and Gal(α1→2GalCer). Both lipids
stimulated human and mouse iNKT cells in the presence of CD1d-expressing antigen-
presenting cells (APC) (Fig. 1a and b). α-GalCer, but not Gal(α1→2GalCer), stimulated iNKT
cells in an APC-free CD1d-Fc fusion protein plate assay (Fig. 1c). In fix/pulse, pulse/fix
experiments α-GalCer stimulated an iNKT cell response under both conditions, whereas Gal
(α1→2GalCer) resulted in cytokine release only under the pulse/fix condition (Fig. 1d).
Together, these data suggest that α-GalCer and Gal(α1→2GalCer) described here can stimulate
human and mouse iNKT cells. Furthermore, Gal(α1→2GalCer), in contrast to α-GalCer,
required uptake and processing to generate the biologically active monoglycosyl ceramide.
In conclusion, we have demonstrated the versatility of both compounds 4 and 10 as crucial
intermediates in practical and high-yielding syntheses of α-GalCer and other biologically
important derivative, such as Gal(α1→2GalCer).
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2 × t-Bu), 0.88 (3H, t, CH3); 13C NMR (75 MHz, CDCl3): δ 98.5 (C-1); HRMS calcd for
C60H79N3O12Si [M+Na]+: 1084.5433, found 1084.5402. Compound 10: 1H NMR (CDCl3): δ 7.97–
8.07 (4H, m, Ar–H), 7.54–7.67 (2H, m, Ar–H), 7.39–7.52 (4H, m, Ar–H), 5.63 (1H, dd, J3,4 = 4.8,
J3,2 = 6.8 Hz, H-3Cer), 5.55 (1H, ddd, J4,5a = 4.2, J4,5b = 8.5 Hz, H-4Cer), 5.43 (d, 1H, J4,3 = 2.6 Hz,
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H-6b), 4.07 (m, 2H, H-5, H-2Cer), 4.00 (m, 1H, H-1aCer), 3.94 (1H, dd, H-2), 3.71 (dd, 1H, J1a,
1b = 10.4, J1b,2 = 6.5 Hz, H-1bCer), 2.40 (d, 1H, J2,OH = 2.8 Hz, OH), 2.13, 2.04, 2.00 (3s, 9H,
3 × OCOCH3), 1.88 (m, 2H, H-5aCer, H-5bCer), 1.21 (m, 24H, CH2), 0.88 (3H, t, CH3); 13C NMR
(75 MHz, CDCl3): δ 97.8 (C-1); HRMS calcd for C44H61N3O13 [M+Na]+: 862.4204, found
862.4199. Compound 11: 1H NMR (CDCl3): δ 7.90–8.03 (8H, m, Ar–H), 7.30–7.59 (12H, m, Ar–
H), 5.58–5.60 (2H, m, H-2′, H-3′), 5.41–5.46 (3H, m, H4′, H4, H-4Cer), 5.32–5.36 (m, 1H, H-3Cer),
5.32 (dd, 1H, J3,2 = 10.1, J3,4 = 3.5 Hz, H-3), 4.86 (d, 1H, J1,2 = 3.6 Hz, H-1), 4.76 (1H, br s, H-1’),
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+: 1372.6278, found 1372.6251. 1: HRMS calcd for C49H97NO9 [M+Na]+: 880.7239, found
880.7218. Compound 12: HRMS calcd for C56H109NO14 [M+Na]+:1042.7848, found 1042.7837.
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tFigure 1.
α-GalCer and Gal(α1→2GalCer) stimulate CD1d-restricted iNKT cells. (a) In vitro activation
of 2.5 × 104 human iNKT cells (clone BM2a.3) in co-culture with 2.5 × 104 U937 cells and
various concentrations of α-GalCer (filled squares) and Gal(α1→2GalCer) (open squares).
After 16 h, cytokines were determined in culture supernatants by ELISA; (b) in vitro activation
of 5 × 104 mouse iNKT cells (hybridoma DN32) in co-culture with 5 × 104 RAW cells
transfected with CD1d (filled symbols) or untransfected (open symbols) and various
concentrations of α-GalCer (squares) and Gal(α1→2GalCer) (circles). After 16 h, cytokine
concentrations were determined in culture supernatants by ELISA; (c) Plate-bound murine
recombinant CD1d-Fc fusion proteins were loaded with α-GalCer (filled squares) or Gal
(α1→2GalCer) (open squares) for 16 h, washed, and 5 × 104iNKT cell hybridomas were added
per well. Cytokines were determined in culture supernatants by ELISA; (d) RAW cells
transfected with CD1d were pulsed with 100 ng/ml of α-GalCer or Gal(α1→2GalCer) for 3 h
and then washed and fixed with glutaraldehyde (filled bars), or fixed and then pulsed for 3 h
(open bars). 105 APCs were co-cultured with 105iNKT cell hybridomas for 16 h and cytokines
were determined in culture supernatants by ELISA. Cytokine responses are expressed as
percent of maximal response. Methods are described elsewhere.
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Reagents and conditions: (a) TBDPSCl, Pyr, quant; (b) BzCl, Pyr, 88%; (c) TBAF, THF, 82%.
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Reagents and conditions: (a) NIS/TfOH, CH2Cl2, 67%; (b) TBAF, THF, quant; (c) NaOMe/
MeOH, 92%; (d) H2, Pd, 88%.
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Reagents and conditions: (a) PhSH, DMF, Cs2CO3, 75%; (b) (CH3)2Si(Cl)2, Pyridine,
CH2Cl2, quant; (c) 5, Pyridine, DMF, 72%; (d) NIS, CH3NO2, 66%; (e) NaOMe/MeOH, quant;
(f) H2, Pd/C, MeOH, 80%; (g) C25H51COCl, THF, NaOAc, 75%.
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Reagents and conditions: (a) NIS/TfOH, CH2Cl2, 67%; (b) TBAF, THF, quant; (c) NaOMe/
MeOH, quant; (d) H2, Pd, MeOH, 80%; (e) C25H51COCl, THF, NaOAc, 78%.
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